Published in Ann Med on November 27, 2015
Efficacy and Safety of IONIS-TTR Rx in Familial Amyloid Polyneuropathy | NCT01737398
Update on hypertrophic cardiomyopathy and a guide to the guidelines. Nat Rev Cardiol (2016) 1.11
Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis. Amyloid (2016) 0.82
Transthyretin Cardiac Amyloidosis in Older Americans. J Card Fail (2016) 0.75
Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics. Mol Ther Nucleic Acids (2016) 0.75
Involvement of Macrophages in the Pathogenesis of Familial Amyloid Polyneuropathy and Efficacy of Human iPS Cell-Derived Macrophages in Its Treatment. PLoS One (2016) 0.75
Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. Circulation (2017) 0.75
Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med (2013) 3.97
Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med (1997) 3.65
Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology (2012) 3.48
Amyloidosis. Annu Rev Med (2006) 3.27
Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med (2000) 3.26
Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci U S A (1990) 2.87
The biological and chemical basis for tissue-selective amyloid disease. Cell (2005) 2.76
Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol (2003) 2.74
Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet (2001) 2.71
Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology (2007) 2.59
Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol (2005) 2.54
(99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging (2013) 2.20
Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum (2006) 2.20
Familial amyloid polyneuropathy. Lancet Neurol (2011) 2.15
Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein. Science (1995) 2.14
Light-chain (AL) amyloidosis: diagnosis and treatment. Clin J Am Soc Nephrol (2006) 2.00
Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging (2010) 1.98
Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation (2009) 1.93
The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve (2007) 1.86
Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas. J Neurol Neurosurg Psychiatry (2012) 1.81
Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature (2010) 1.81
Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol (2005) 1.78
Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging (2014) 1.78
Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA (2013) 1.69
Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis (2013) 1.68
Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging (2014) 1.65
Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet (1991) 1.60
Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol (2005) 1.55
Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol (2013) 1.54
High incidence of thrombotic complications early after liver transplantation for familial amyloidotic polyneuropathy. Transpl Int (2008) 1.52
Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest (2004) 1.50
Light chain (AL) amyloidosis: update on diagnosis and management. J Hematol Oncol (2011) 1.48
Transthyretin (TTR) cardiac amyloidosis. Circulation (2012) 1.40
Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy. J Intern Med (1994) 1.39
Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Lung Transplant (2004) 1.36
Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis. Transplantation (1998) 1.35
Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation (2004) 1.35
Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid (2006) 1.34
Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc (2014) 1.31
Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med (2008) 1.30
Digoxin sensitivity in amyloid cardiomyopathy. Circulation (1981) 1.28
Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form. Arch Neurol (2002) 1.19
Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid (2008) 1.19
Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve (2006) 1.17
Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg (2002) 1.16
THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin (2012) 1.16
Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type. Transplantation (2002) 1.16
Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy. J Neurol (2013) 1.14
The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain (2000) 1.13
Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild-type transthyretin. Biochem Biophys Res Commun (2000) 1.13
Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative? Transplantation (2015) 1.13
Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail (2014) 1.12
Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res (2013) 1.09
Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. Am J Cardiol (1985) 1.09
Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J (2012) 1.07
Long-term data from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR). Amyloid (2011) 1.07
Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis. J Pathol (2008) 1.06
Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Br J Haematol (2010) 1.04
Variation in amount of wild-type transthyretin in different fibril and tissue types in ATTR amyloidosis. J Mol Med (Berl) (2010) 1.03
The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients. Am Heart J (2012) 1.03
Transthyretin cardiac amyloidoses in older North Americans. J Am Geriatr Soc (2012) 1.03
Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology (2012) 1.02
Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years. Am J Transplant (2007) 1.01
Heart transplantation for homozygous familial transthyretin (TTR) V122I cardiac amyloidosis. Am J Transplant (2008) 1.00
Update on treatment of light chain amyloidosis. Haematologica (2014) 1.00
Diflunisal for ATTR cardiac amyloidosis. Congest Heart Fail (2012) 0.99
Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis. Amyloid (2013) 0.98
Serum amyloid P component scintigraphy in familial amyloid polyneuropathy: regression of visceral amyloid following liver transplantation. Eur J Nucl Med (1998) 0.98
Synergy of combined doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models. J Transl Med (2010) 0.98
Progression of transthyretin amyloid neuropathy after liver transplantation. Neurology (2010) 0.98
Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. Eur J Neurol (2013) 0.95
Heart complications in familial transthyretin amyloidosis: impact of age and gender. Amyloid (2010) 0.95
Recent progress in the understanding and treatment of transthyretin amyloidosis. J Clin Pharm Ther (2014) 0.92
Phenotypic and genotypic heterogeneity in transthyretin-related cardiac amyloidosis: towards tailoring of therapeutic strategies? Amyloid (2006) 0.91
Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: state of the art review and focus on emerging nuclear techniques. J Nucl Cardiol (2014) 0.90
Amyloid fibril composition as a predictor of development of cardiomyopathy after liver transplantation for hereditary transthyretin amyloidosis. Transplantation (2012) 0.90
Retrospective study of a TTR FAP cohort to modify NIS+7 for therapeutic trials. J Neurol Sci (2014) 0.89
Epidemiology of familial amyloid polyneuropathy in Japan: Identification of a novel endemic focus. J Neurol Sci (2008) 0.88
Amyloid neuropathies. Curr Opin Neurol (2012) 0.88
Regional difference and similarity of familial amyloidosis with polyneuropathy in France. Amyloid (2012) 0.88
Effects of sildenafil citrate (viagra) on cardiac repolarization and on autonomic control in subjects with chronic heart failure. Am Heart J (2002) 0.87
Marked regression of abdominal fat amyloid in patients with familial amyloid polyneuropathy during long-term follow-up after liver transplantation. Liver Transpl (2008) 0.87
Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J (2011) 0.87
Ten years of experience with liver transplantation for familial amyloid polyneuropathy in Japan: outcomes of living donor liver transplantations. Intern Med (2005) 0.86
Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study. Neurology (2015) 0.86
Usefulness of labial salivary gland biopsy in familial amyloid polyneuropathy Portuguese type. Amyloid (2009) 0.85
Quantification of transthyretin kinetic stability in human plasma using subunit exchange. Biochemistry (2014) 0.85
Recent advances in the treatment of familial amyloid polyneuropathy. Ther Adv Neurol Disord (2013) 0.84
Combined heart and liver transplantation: a single-center experience. Transplantation (2009) 0.84
Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center. Aging health (2013) 0.84
Prophylactic pacemaker implantation in familial amyloid polyneuropathy. Heart Rhythm (2012) 0.83
Rate of progression of transthyretin amyloidosis. Am J Cardiol (2011) 0.83
Ten-year follow-up of peripheral nerve function in patients with familial amyloid polyneuropathy after liver transplantation. J Neurol (2008) 0.83
Assessment of nonsteroidal anti-inflammatory drug-induced cardiotoxicity. Expert Opin Drug Metab Toxicol (2013) 0.82
Tyr78Phe Transthyretin Mutation with Predominant Motor Neuropathy as the Initial Presentation. Case Rep Neurol (2011) 0.81
Pulsed tissue Doppler and strain imaging discloses early signs of infiltrative cardiac disease: a study on patients with familial amyloidotic polyneuropathy. Eur J Echocardiogr (2006) 0.81
Liver transplantation and combined liver-heart transplantation in patients with familial amyloid polyneuropathy: a single-center experience. Liver Transpl (2010) 0.81
Prenatal diagnosis of hereditary amyloidosis in a Portuguese family. Am J Med Genet (1991) 0.80
Preimplantation genetic diagnosis for familial amyloidotic polyneuropathy (FAP). Prenat Diagn (2001) 0.80